Edison Comments on Micromet

Edison Investment Research provided color on Micromet's MITI collaboration with Amgen AMGN in a research report published today. In the report, Edison Investment Research states, "Micromet has formed a major collaboration with Amgen to develop its BiTE antibodies to treat solid tumours. It is the fifth alliance with a major pharmaceutical company to create BiTE antibodies. Recently announced clinical data further demonstrates the potential of the technology platform. Micromet's strong balance sheet, alliances and technology make it an attractive investment proposition." Shares of Micromet were trading at $6.28 at the time of posting, down 1.26% from Tuesday's market close.